



Special Issue on  
**Antiretroviral Therapy, Milestones, and  
Impediments: Perspective of the Resource Limited  
Countries**

# CALL FOR PAPERS

In resource limited countries, HIV/AIDS continues to infect and affect many populations. Achieving the vision of zero new HIV infections and zero AIDS-related deaths in these countries requires that everyone needing HIV treatment has access to life-saving medication and other HIV prevention services. Antiretroviral therapy (ART) is one of the most effective tools available and it is an essential part of an efficient, sustainable AIDS response. Despite the significant clinical benefits, emergence of adverse effects due to ART is becoming a major safety concern threatening to limit their use. We query “do the milestones (clinical benefits) overshadow the impediments (adverse effects) of ART”?

The purpose of this special issue is to publish high-quality research papers as well as review articles addressing the milestones and impediments (or both) of ART with special emphasis on resource limited countries. The focus of each paper, whether addressing milestones, impediments, or both, should be specified under each of the suggested topics. Original, high quality contributions that are not yet published or that are not currently under review by other journals or peer-reviewed conferences are sought.

Potential topics include, but are not limited to:

- ▶ ARV delivery and monitoring programs
- ▶ Effectiveness of ARV
- ▶ Host and viral pharmacodynamics impacting ARV treatment outcomes
- ▶ ARV potency and special emphasis on generics
- ▶ ARV pharmacokinetics
- ▶ Adverse reactions (toxicity) associated with ARV
- ▶ ARV drug resistance monitoring
- ▶ Advances in ARV drug resistance monitoring

Authors can submit their manuscripts via the Manuscript Tracking System at <http://mts.hindawi.com/submit/journals/bmri/infectious.diseases/antith/>.

**Lead Guest Editor**

Musa O. Ngayo, Kenya Medical  
Research Institute, Nairobi, Kenya  
[musaotieno@yahoo.com](mailto:musaotieno@yahoo.com)

**Guest Editors**

Carole Devaux, Luxembourg Institute of  
Health, Strassen, Luxembourg  
[carole.devaux@lih.lu](mailto:carole.devaux@lih.lu)

Dara Lehman, Fred Hutchinson Cancer  
Research Center Seattle, Seattle, USA  
[dlehman@fhcrc.org](mailto:dlehman@fhcrc.org)

Bhavna Chohan, University of  
Washington, Seattle, USA  
[bchohan@uw.edu](mailto:bchohan@uw.edu)

**Manuscript Due**

Friday, 1 July 2016

**First Round of Reviews**

Friday, 23 September 2016

**Publication Date**

Friday, 18 November 2016